Rocket Pharmaceuticals Inc stock is traded at $2.45, with a volume of 1,224,137. It is down -3.16% in the last 24 hours and down -4.30% over the past month. Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Previous Close:
$2.53
Open:
$2.50
24h Volume:
1,224,137
Relative Volume:
0.76
Market Cap:
$268.95M
Revenue:
-
Net Income/Loss:
-$209.38M
P/E Ratio:
-
EPS:
-$1.88
Net Cash Flow:
-$179.81M
1W Performance:
-2.39%
1M Performance:
-4.30%
6M Performance:
-32.51%
1Y Performance:
-22.22%
1-Day Range:
$2.40$2.58
1-Week Range:
$2.30$2.66
52-Week Range:
$2.17$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
646-440-9100Address
350 FIFTH AVENUE, NEW YORK, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS